Company intelligence / Profile preview

Oscar A-Co KK

Ownership: Private
Development stage: Other

Overview

Oscar A-Co KK was a special purpose company established by Blackstone to acquire Takeda Consumer Healthcare Company Limited (TCHC). The acquisition was completed on March 31, 2021, and TCHC subsequently operated as Alinamin Pharmaceutical Co., Ltd. The acquired portfolio included over-the-counter medicines and health products that generated total revenues of over JPY 60 billion in fiscal year 2019, with strong regional brands including Alinamin (Japan's first vitamin B1 preparation) and Benza (a cold remedy)[1][4][5].

Industry: Investors

Beyond the preview

Go deeper on Oscar A-Co KK.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Oscar A-Co KK.

Explore the full profile